(Total Views: 484)
Posted On: 07/22/2019 10:46:54 AM
Post# of 72440
And I reiterate: Alfasigma already has a drug used for IBS and other intestinal infections, so the fact that they want Brilacidin TOO tells you something.
I checked -- Alfasigma's drug Xifaxan (Rifaxamin) is very, very expensive in the U.S. but within reason in Canada. It seems to be marketed by Salix in North America. Their first patent approval was May, 2004, and they have other patents as late at 2010.
This means they're planning for a future when generics for this drug will knock the price way down, and that future is not all that far away for them. They really NEED for Brilacidin to be developed.
https://www.drugpatentwatch.com/p/tradename/XIFAXAN
I checked -- Alfasigma's drug Xifaxan (Rifaxamin) is very, very expensive in the U.S. but within reason in Canada. It seems to be marketed by Salix in North America. Their first patent approval was May, 2004, and they have other patents as late at 2010.
This means they're planning for a future when generics for this drug will knock the price way down, and that future is not all that far away for them. They really NEED for Brilacidin to be developed.
https://www.drugpatentwatch.com/p/tradename/XIFAXAN
(3)
(0)Scroll down for more posts ▼
